Stanozolol

DB06718

small molecule approved vet_approved

Deskripsi

Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes.

Struktur Molekul 2D

Berat 328.4916
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 24 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

186 Data
Cyclosporine The risk or severity of liver damage can be increased when Stanozolol is combined with Cyclosporine.
Dicoumarol Stanozolol may increase the anticoagulant activities of Dicoumarol.
Phenindione Stanozolol may increase the anticoagulant activities of Phenindione.
Warfarin Stanozolol may increase the anticoagulant activities of Warfarin.
Phenprocoumon Stanozolol may increase the anticoagulant activities of Phenprocoumon.
Acenocoumarol Stanozolol may increase the anticoagulant activities of Acenocoumarol.
4-hydroxycoumarin Stanozolol may increase the anticoagulant activities of 4-hydroxycoumarin.
Coumarin Stanozolol may increase the anticoagulant activities of Coumarin.
(R)-warfarin Stanozolol may increase the anticoagulant activities of (R)-warfarin.
Ethyl biscoumacetate Stanozolol may increase the anticoagulant activities of Ethyl biscoumacetate.
Fluindione Stanozolol may increase the anticoagulant activities of Fluindione.
Clorindione Stanozolol may increase the anticoagulant activities of Clorindione.
Diphenadione Stanozolol may increase the anticoagulant activities of Diphenadione.
Tioclomarol Stanozolol may increase the anticoagulant activities of Tioclomarol.
(S)-Warfarin Stanozolol may increase the anticoagulant activities of (S)-Warfarin.
Insulin human Stanozolol may increase the hypoglycemic activities of Insulin human.
Insulin lispro Stanozolol may increase the hypoglycemic activities of Insulin lispro.
Insulin glargine Stanozolol may increase the hypoglycemic activities of Insulin glargine.
Insulin pork Stanozolol may increase the hypoglycemic activities of Insulin pork.
Troglitazone Stanozolol may increase the hypoglycemic activities of Troglitazone.
Glimepiride Stanozolol may increase the hypoglycemic activities of Glimepiride.
Sulfisoxazole Stanozolol may increase the hypoglycemic activities of Sulfisoxazole.
Disopyramide Stanozolol may increase the hypoglycemic activities of Disopyramide.
Acarbose Stanozolol may increase the hypoglycemic activities of Acarbose.
Metformin Stanozolol may increase the hypoglycemic activities of Metformin.
Sulfadiazine Stanozolol may increase the hypoglycemic activities of Sulfadiazine.
Rosiglitazone Stanozolol may increase the hypoglycemic activities of Rosiglitazone.
Acetohexamide Stanozolol may increase the hypoglycemic activities of Acetohexamide.
Quinine Stanozolol may increase the hypoglycemic activities of Quinine.
Miglitol Stanozolol may increase the hypoglycemic activities of Miglitol.
Chlorpropamide Stanozolol may increase the hypoglycemic activities of Chlorpropamide.
Nateglinide Stanozolol may increase the hypoglycemic activities of Nateglinide.
Pentamidine Stanozolol may increase the hypoglycemic activities of Pentamidine.
Mifepristone Stanozolol may increase the hypoglycemic activities of Mifepristone.
Tolazamide Stanozolol may increase the hypoglycemic activities of Tolazamide.
Repaglinide Stanozolol may increase the hypoglycemic activities of Repaglinide.
Phenformin Stanozolol may increase the hypoglycemic activities of Phenformin.
Sulfamethoxazole Stanozolol may increase the hypoglycemic activities of Sulfamethoxazole.
Glyburide Stanozolol may increase the hypoglycemic activities of Glyburide.
Glipizide Stanozolol may increase the hypoglycemic activities of Glipizide.
Gliclazide Stanozolol may increase the hypoglycemic activities of Gliclazide.
Tolbutamide Stanozolol may increase the hypoglycemic activities of Tolbutamide.
Pioglitazone Stanozolol may increase the hypoglycemic activities of Pioglitazone.
Bromocriptine Stanozolol may increase the hypoglycemic activities of Bromocriptine.
Gliquidone Stanozolol may increase the hypoglycemic activities of Gliquidone.
Mitiglinide Stanozolol may increase the hypoglycemic activities of Mitiglinide.
Sitagliptin Stanozolol may increase the hypoglycemic activities of Sitagliptin.
Sunitinib Stanozolol may increase the hypoglycemic activities of Sunitinib.
Exenatide Stanozolol may increase the hypoglycemic activities of Exenatide.
Mecasermin Stanozolol may increase the hypoglycemic activities of Mecasermin.
Pramlintide Stanozolol may increase the hypoglycemic activities of Pramlintide.
Glisoxepide Stanozolol may increase the hypoglycemic activities of Glisoxepide.
Insulin aspart Stanozolol may increase the hypoglycemic activities of Insulin aspart.
Insulin detemir Stanozolol may increase the hypoglycemic activities of Insulin detemir.
Insulin glulisine Stanozolol may increase the hypoglycemic activities of Insulin glulisine.
Glymidine Stanozolol may increase the hypoglycemic activities of Glymidine.
AICA ribonucleotide Stanozolol may increase the hypoglycemic activities of AICA ribonucleotide.
Buformin Stanozolol may increase the hypoglycemic activities of Buformin.
Vildagliptin Stanozolol may increase the hypoglycemic activities of Vildagliptin.
Voglibose Stanozolol may increase the hypoglycemic activities of Voglibose.
NN344 Stanozolol may increase the hypoglycemic activities of NN344.
AMG-222 Stanozolol may increase the hypoglycemic activities of AMG-222.
Bisegliptin Stanozolol may increase the hypoglycemic activities of Bisegliptin.
Alogliptin Stanozolol may increase the hypoglycemic activities of Alogliptin.
Dapagliflozin Stanozolol may increase the hypoglycemic activities of Dapagliflozin.
Saxagliptin Stanozolol may increase the hypoglycemic activities of Saxagliptin.
Liraglutide Stanozolol may increase the hypoglycemic activities of Liraglutide.
Gosogliptin Stanozolol may increase the hypoglycemic activities of Gosogliptin.
Linagliptin Stanozolol may increase the hypoglycemic activities of Linagliptin.
Canagliflozin Stanozolol may increase the hypoglycemic activities of Canagliflozin.
Glibornuride Stanozolol may increase the hypoglycemic activities of Glibornuride.
Benfluorex Stanozolol may increase the hypoglycemic activities of Benfluorex.
Empagliflozin Stanozolol may increase the hypoglycemic activities of Empagliflozin.
Albiglutide Stanozolol may increase the hypoglycemic activities of Albiglutide.
Dulaglutide Stanozolol may increase the hypoglycemic activities of Dulaglutide.
Lobeglitazone Stanozolol may increase the hypoglycemic activities of Lobeglitazone.
Netoglitazone Stanozolol may increase the hypoglycemic activities of Netoglitazone.
Rivoglitazone Stanozolol may increase the hypoglycemic activities of Rivoglitazone.
Ciglitazone Stanozolol may increase the hypoglycemic activities of Ciglitazone.
Lixisenatide Stanozolol may increase the hypoglycemic activities of Lixisenatide.
Insulin beef Stanozolol may increase the hypoglycemic activities of Insulin beef.
Insulin degludec Stanozolol may increase the hypoglycemic activities of Insulin degludec.
Insulin peglispro Stanozolol may increase the hypoglycemic activities of Insulin peglispro.
Insulin tregopil Stanozolol may increase the hypoglycemic activities of Insulin tregopil.
Ipragliflozin Stanozolol may increase the hypoglycemic activities of Ipragliflozin.
Dutogliptin Stanozolol may increase the hypoglycemic activities of Dutogliptin.
Allicin Stanozolol may increase the hypoglycemic activities of Allicin.
Tofogliflozin Stanozolol may increase the hypoglycemic activities of Tofogliflozin.
Ertugliflozin Stanozolol may increase the hypoglycemic activities of Ertugliflozin.
2,4-thiazolidinedione Stanozolol may increase the hypoglycemic activities of 2,4-thiazolidinedione.
Teneligliptin Stanozolol may increase the hypoglycemic activities of Teneligliptin.
Omarigliptin Stanozolol may increase the hypoglycemic activities of Omarigliptin.
Carmegliptin Stanozolol may increase the hypoglycemic activities of Carmegliptin.
Gemigliptin Stanozolol may increase the hypoglycemic activities of Gemigliptin.
Anagliptin Stanozolol may increase the hypoglycemic activities of Anagliptin.
Evogliptin Stanozolol may increase the hypoglycemic activities of Evogliptin.
Sotagliflozin Stanozolol may increase the hypoglycemic activities of Sotagliflozin.
Balaglitazone Stanozolol may increase the hypoglycemic activities of Balaglitazone.
Remogliflozin etabonate Stanozolol may increase the hypoglycemic activities of Remogliflozin etabonate.
Carbutamide Stanozolol may increase the hypoglycemic activities of Carbutamide.

Target Protein

Androgen receptor AR
Glucocorticoid binding proteins

Referensi & Sumber

Artikel (PubMed)
  • PMID: 18447143
    Guilarte M, Luengo O, Nogueiras C, Labrador-Horrillo M, Munoz E, Lopez A, Cardona V: Acquired angioedema associated with hereditary angioedema due to C1 inhibitor deficiency. J Investig Allergol Clin Immunol. 2008;18(2):126-30.
  • PMID: 20020362
    Thevis M, Schanzer W: Synthetic anabolic agents: steroids and nonsteroidal selective androgen receptor modulators. Handb Exp Pharmacol. 2010;(195):99-126. doi: 10.1007/978-3-540-79088-4_5.
  • PMID: 17765757
    Sloane DE, Lee CW, Sheffer AL: Hereditary angioedema: Safety of long-term stanozolol therapy. J Allergy Clin Immunol. 2007 Sep;120(3):654-8.

Contoh Produk & Brand

Produk: 0 • International brands: 3
International Brands
  • Stromba
  • Winstrol
  • Winstrol Depot

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul